Journals
  Publication Years
  Keywords
Search within results Open Search
Please wait a minute...
For Selected: Toggle Thumbnails
Alphaherpesvirus-vectored vaccines against animal diseases: Current progress
HU Yang, WANG Ming-shu, CHENG An-chun, JIA Ren-yong, YANG Qiao, WU Ying, LIU Ma-feng, ZHAO Xin-xin, ZHU De-kang, CHEN Shun, ZHANG Sha-qiu, WANG Yin, GAO Qun, OU Xu-min, MAO Sai, WEN Xing-jian, XU Zhi-wen, CHEN Zheng-li, ZHU Ling, LUO Qi-hui, TIAN Bin, PAN Lei-chang, Mujeeb Ur REHMAN, LIU Yun-ya, YU Yan-ling, ZHANG Ling, CHEN Xiao-yue
2020, 19 (8): 1928-1940.   DOI: 10.1016/S2095-3119(20)63175-6
Abstract242)      PDF in ScienceDirect      
Recombinant virus-vectored vaccines are novel agents that can effectively activate specific and nonspecific immunity, are multivalent and multieffective, and have high safety ratings.  Animal alphaherpesviruses have a large genome, contain multiple nonessential regions that do not affect viral replication and are capable of accepting the insertion of an exogenous gene and expressing the antigen protein.  Furthermore, animal alphaherpesviruses have a wide host spectrum, can replicate in the host and continuously stimulate the animal to produce immunity to the corresponding pathogen, thus making them ideal carriers for recombinant virus-vectored vaccines.  With the development of gene-editing technology, recombinant viruses capable of expressing foreign genes can be constructed by various methods.  Currently, studies on recombinant virus-vectored vaccines constructed based on animal alphaherpesviruses have involved poultry, pigs, cattle, sheep, and companion animals.  Studies have shown that the construction of recombinant animal alphaherpesviruses enables the acquisition of immunity to multiple diseases.  This article mainly summarizes the current progress on animal alphaherpesvirus-vectored vaccines, aiming to provide reference for the development of new animal alphaherpesvirus-vectored vaccines.
 
Reference | Related Articles | Metrics
Immunogenicity and protective efficacy of DHBV DNA vaccines expressing envelope and capsid fusion proteins in ducks delivered by attenuated Salmonella typhimurium
LIU Si-yang, JIA Ren-yong, LI Qing-qing, FENG Dai-shen, SHEN Hao-yue, YANG Cui, WANG Ming-shu, ZHU De-kang, CHEN Shun, LIU Ma-feng, ZHAO Xin-xin, YIN Zhong-qiong, JING Bo, CHENG An-chun
2018, 17 (04): 928-939.   DOI: 10.1016/S2095-3119(17)61829-X
Abstract495)      PDF in ScienceDirect      
Duck hepatitis B virus (DHBV) shares many basic characteristics with hepatitis B virus (HBV) and is an attractive model for vaccine development.  In this study, DHBV DNA vaccines were designed to express envelope and capsid fusion proteins to enhance the breadth of immune response in ducks.  Attenuated Salmonella typhimurium (SL7207) was used as a carrier and adjuvant to boost the magnitude of immune response.  Based on this strategy, novel DNA vaccines (SL7207-pVAX1-LC and SL7207-pVAX1-SC) were generated.  Growth kinetics, genetic stabilities and relative transcription levels of the L, S and C genes introduced by these vaccine strains were measured before inoculation to guarantee safety and efficacy.  The relative transcript levels of the CD4 and CD8 T genes and the antibody levels (IgY) in ducks receiving the vaccines were higher than those in single gene delivered groups.  Additionally, the copy number of covalently closed circular DNA in hepatocytes after DHBV challenge also provided evidence that our fusion vaccines could enhance the protective efficiency against DHBV infection in ducks.
Reference | Related Articles | Metrics
The codon-optimized capsid gene of duck circovirus can be highly expressed in yeast and self-assemble into virus-like particles
YANG Cui, XU Yu, JIA Ren-yong, LIU Si-yang, WANG Ming-shu, ZHU De-kang, CHEN Shun, LIU Ma-feng, ZHAO Xin-xin, SUN Kun-feng, JING Bo, YIN Zhong-qiong, CHENG An-chun
2017, 16 (07): 1601-1608.   DOI: 10.1016/S2095-3119(16)61605-2
Abstract863)      PDF in ScienceDirect      
    The capsid (Cap) protein, which is the only structural protein of duck circovirus (DuCV), is the most important antigen for the development of vaccines against DuCV and the virus’s serological diagnostic methods. In order to use yeast expression system to produce a large quantities of DuCV Cap protein which is close to its natural form to display the antigen peptides perfectly, the Cap gene was optimized into the codon-optimized capsid (Opt-Cap) gene towards the preference of yeast firstly. Then, the genes of Cap and Opt-Cap were separately cloned into pPIC9K plasmid and transformed into Picha pastoris GS115. The strains that displayed the phenotype of Mut+ and contained multiple inserts of expression cassette were selected from those colonies. After the induction expression, the secretory type of Cap protein, which was about 43 kDa, was best expressed under 0.5% (v/v) methanol and sorbitol induction. Compared with the Cap gene, the expression level of Opt-Cap gene was much higher. What’s more, the purified Cap protein had a good reactivity to its specific polyclone antibody and DuCV-positive serum, and it was able to self-assemble into virus-like particles (VLPs). These VLPs, with a diameter of 15–20 nm and without a nucleic acid structure, showed a high level of similarity to DuCV particles in size and shape. All of the results demonstrated that, based on the codon-optimization, it is suitable to use the P. pastoris expression system to produce DuCV VLPs on a large scale. It is the first time that a large amounts of DuCV VLPs were produced successfully in P. pastoris, which might be particularly useful for the further studies of serological diagnosis and vaccines of DuCV.
Reference | Related Articles | Metrics